Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.13 (
acetyl-CoA synthetase
)
451
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
The identification of prognostic markers for non-small-cell lung carcinoma (NSCLC) is needed for clinical practice. The metabolism-reprogramming marker
ketohexokinase
(
KHK
)-A and
acetyl-CoA synthetase
2 (ACSS2) phosphorylation at S659 (ACSS2 pS659) play important roles in tumorigenesis and tumor development. However, the clinical significance of
KHK
-A and ACSS2 pS659 in NSCLC is largely unknown.
Methods:
The expression levels of
KHK
-A and ACSS2 pS659 were assessed by immunohistochemistry analyses of surgical specimens from 303 NSCLC patients. The prognostic values of
KHK
-A and ACSS2 pS659 were evaluated by Kaplan-Meier methods and Cox regression models.
Results:
The expression levels of
KHK
-A and ACSS2 pS659 were significantly higher in NSCLC tissues than those in adjacent non-tumor tissues (
P
< 0.0001).
KHK
-A or ACSS2 pS659 alone and the combination of
KHK
-A and ACSS2 pS659 were inversely correlated with overall survival in NSCLC patients (
P
< 0.001). The multivariate analysis indicated that
KHK
-A or ACSS2 pS659 and
KHK
-A/ACSS2 pS659 were independent prognostic biomarkers for NSCLC (
P
= 0.008 for
KHK
-A,
P
< 0.001 for ACSS2 pS659, and
P
< 0.001 for
KHK
-A/ACSS2 pS659). Furthermore, the combination of
KHK
-A and ACSS2 pS659 can be used as a prognostic indicator for all stages of NSCLC.
Conclusions:
KHK
-A or ACSS2 pS659 alone and the combination of
KHK
-A and ACSS2 pS659 can be used as prognostic markers for NSCLC. Our findings highlight the important role of metabolic reprogramming in NSCLC progression.
...
PMID:Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma. 3175 Feb 40
